NCI Budget and RPG Pool

Patrick McGarey, J.D., MBA Assoc. Director for Finance & Legislation

NCAB Subcommittee on Planning & Budget September 1, 2020 patrick.mcgarey2 @nih.gov



... Flashback to Dr. Lowy 12/3/19
Presentation

NCI Budget & RPG Pool

Douglas R. Lowy, M.D. Principal Deputy Director


Joint Meeting of the National Cancer Advisory Board Board of Scientific Advisors

December 3, 2019






How does NCI spend its money?







FY 2019 Research Project Grants




Centers & SPORES





Competing R01 applications vs. budgets for NCI & RPGs: Percent change since FY 2013





... Flashback to Dr. Sharpless 2/11/20 Presentation

NCI Director's Report

Norman E. Sharpless, M.D.


Virtual National Cancer Advisory Board Meeting February 11, 2020





NCI Appropriations FY 2015 – 2020 (in millions)

21st Century Cures Act - orange Childhood Cancer Initiative - green






NCI FY 2020 Appropriation from Congress

DIVISION A—DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION, AND RELATED AGENCIES

APPROPRIATIONS ACT, 2020


NCI Paylines.—Grant applications to NCI have increased by approximately 50 percent since 2013, outpacing available funding, with requests for cancer research ten-fold greater than other Institutes. With such a high demand for NCI grants, only a fraction of this research is funded. To support more awards and improve success rates, the agreement provides \$212,500,000 to prioritize competing grants and sustain commitments to continuing grants.



NCI FY 2020 Competing Grant Policies		
Grant Type	FY 2020	FY 2019
R01 Grants for Established & New Investigators	10th Percentile	8th Percentile
R01 Grants for Early Stage Investigators (ESIs)	15th Percentile	14th Percentile
R21 Exploratory / Developmental Grants	9th Percentile	7th Percentile



NCI RPG Pool and R01 Payline – FY 2016-20





In addition to these RPGs, in FY19 NCI supported over \$1.1B of extramural research grants through non-RPG mechanisms, e.g.,

- Clinical trials (U10)
- Cancer Centers (P30)
- SPORES (U54)
- Training (F, K, T)

Does not include SBIR/STTR or Admin Supplements
*FY 2017 includes competing first-year costs and awards from Cancer Moonshot fully funded awards.

... Flashback to Dr. Lowy's 6/15/20 Presentation

Update: COVID-19 Serology and Immunology Capacity Building

Douglas R. Lowy, M.D. Principal Deputy Director

^{2nd} Virtual Meeting of the National Cancer Advisory Board and the Board of Scientific Advisors

June 15, 2020





NCI supplemental funding from Congress

- Enacted April 24th
- \$306M for NCI to develop, validate, improve, and implement serological testing and associated technologies
- COVID-19 focused and distinct from annual appropriation

134 STAT, 620

PUBLIC LAW 116-139—APR. 24, 2020

Public Law 116–139 116th Congress

An Act

Apr. 24, 2020 [H.R. 266]

Paycheck Protection Program and Health Care Enhancement Act. 15 USC 9001 note. Making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2019, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "Paycheck Protection Program and Health Care Enhancement Act".

SEC. 2. TABLE OF CONTENTS.

The table of contents for this Act is as follows:

Sec. 1. Short title.

Sec. 2. Table of contents.

Sec. 3. References.

Proposed Serological Sciences Network for

SARS-CoV-2 U01 **CBC** U01 **CBC** U01 **CBC** U01 **Network Coordinating** Center **CBC** U01 **FNL Serology** Lab **CBC U54 CBC U54 U54 U54** U54 U54 ATIONAL CANCER INSTITUTE

4-8 CBCs: Serological Sciences Capacity Building Centers (RFP)

4-8 U54s: Serological Sciences Centers of Excellence (RFA)

5-10 U01s: Serological sciences projects (RFA)

NCI Response to COVID-19

Three NCI Notices (April) -

- Urgent Competitive Revisions & Admin. Supps (CA-20-042)
- SBIR/STTR Urgent Competitive Revisions & Admin. Supps (CA-20-043)
- Redirecting Grant Funds to COVID-19-Related Research (CA-20-054)

NIH / NCI issued policy flexibility on -

- Deadlines
- Paying salaries & stipends
- Project periods & reporting
- ESI & trainee eligibility

Guidance and Support

- FAQs on repurposing grant funds to conduct COVID-19 research
- FAQs on expedited timeframes for NCI decisions



Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled . . .

Budget Trends & FY 2021



- TBD when FY 2021 final funding will arrive?
 - FY 2017 in May 2017; FY 2013 in March 2013, FY 2009 in March 2009
- TBD who will be in charge?
- Funding trend is strong, but will it continue?
 - Since FY 2016 NIH budget is +\$9.4B (up 29%)
 - Since FY 2016 NCI budget is +\$1.2B (up 23.5%)
- No FY 2021 Senate bill, but House is +\$54M (up 0.8%) for NCI*
 - *House also includes \$5B (NIH-wide) for lab productivity losses due to pandemic

Additional Resources



NCI Budget

- Sharpless on <u>Details of NCI FY 2020 Budget Increase</u>
- McGarey on NCI Budgets During a Continuing Resolution

COVID-19

- Singer on <u>SeroNet for COVID-19 Response</u>
- Lowy & Singer provide <u>Further Details on SeroNet</u>
- Bogler on <u>Cancer Research Training in the Era of COVID-19</u>



www.cancer.gov www.cancer.gov/espanol

1-800-4CANCER